论文部分内容阅读
钙拮抗剂在试管和活体试验都表明有抑制胰岛素分泌的作用。有报告钙拮抗剂可使胰岛肿瘤的患者的自发性低血糖现象减少。因此,本文作者对进行糖耐量试验(0GTT)后,血中免疫反应胰岛素(IRI)过剩反应型的倾倒综合征患者2例及原发性反应性低血糖1例为对象,应用钙拮抗剂治疗,观察疗效。前2例服硝苯吡啶胶囊,每日30mg;后1例用盐酸硫氮(艹卓)酮(diltiazem—HCl),每日90mg。两药均为1日3次,餐后立即分服。此3例的餐后低血糖反应在钙拮抗剂应用1个月后消失,前2例在停用钙拮抗剂后2～3周由于再出现餐后低血糖反应,故再投钙拮抗剂,低血糖反应症状消失。3例均在治疗前、后及停用钙拮抗剂后作OGTT,
Calcium antagonists have been shown to inhibit insulin secretion both in vitro and in vivo. Calcium antagonists have been reported to reduce spontaneous hypoglycemia in patients with islet tumors. Therefore, the authors of this study performed two trials of glucose tolerance test (0GTT), two patients with IRI-induced dumping syndrome and one with primary reactive hypoglycemia, and treated with calcium antagonist , Observe the effect. The first two patients took nifedipine capsules, 30mg daily; after 1 case with diltiazem hydrochloride (diltiazem-HCl), 90mg daily. Two drugs are on the 1st 3 times, immediately after meals service. The 3 cases of postprandial hypoglycemia response disappeared after 1 month of calcium antagonist application, the first two cases of calcium antagonists in the disabled 2 to 3 weeks after the re-occurrence of postprandial hypoglycemia, it is recommended to vote calcium antagonists, Symptoms of hypoglycemia disappear. 3 cases were in the treatment before and after the withdrawal of calcium antagonists for OGTT,